Morphine dependence
disease diseaseOn this page
Summary
Morphine dependence (MONDO:0005531) is a disease and 3 clinical trials. Top therapeutic interventions include buprenorphine and naloxone. A subtype of opiate dependence — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | morphine dependence |
| Mondo ID | MONDO:0005531 |
| EFO | EFO:0005612 |
| MeSH | D009021 |
| DOID | DOID:2560 |
| ICD-11 | 337142707 |
| SNOMED CT | 231479000 |
| UMLS | C0026552 |
| MedGen | 7706 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of opiate dependence. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › substance-related disorder › substance dependence › drug dependence › opiate dependence › morphine dependence
Related subtypes (1): heroin dependence
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
No drug has an approved disease-direct ChEMBL indication for this disease.
2 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Buprenorphine | Phase 3 |
| Naloxone | Phase 3 |
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00032955 | PHASE3 | COMPLETED | Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1 |
| NCT00032968 | PHASE3 | COMPLETED | Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1 |
| NCT04495673 | Not specified | TERMINATED | Combining Neuro-Imaging and Non-Invasive Brain Stimulation for Clinical Intervention in Opioid Use Disorder |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BUPRENORPHINE | 4 | 2 |
| NALOXONE | 4 | 2 |
| CHEMBL452845 | 0 | 2 |
Related Atlas pages
- Drugs: Buprenorphine, Naloxone